Eszopiclone
- Generic Name
- Eszopiclone
- Brand Names
- Lunesta
- Drug Type
- Small Molecule
- Chemical Formula
- C17H17ClN6O3
- CAS Number
- 138729-47-2
- Unique Ingredient Identifier
- UZX80K71OE
- Background
Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as cyclopyrrolones. Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a safer alternative to other drugs used for insomnia.
...
- Indication
Eszopiclone is indicated for the treatment of insomnia.
- Associated Conditions
- Insomnia
- Associated Therapies
- -
Eszopiclone and Inflammatory Mediators in Patients With Acute Coronary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2016-12-20
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 5
- Registration Number
- NCT00822679
- Locations
- 🇺🇸
Southern Arizona VA Health Care System, Tucson, Arizona, United States
Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2012-10-03
- Lead Sponsor
- Lehigh Center for Clinical Research
- Target Recruit Count
- 60
- Registration Number
- NCT00813735
- Locations
- 🇺🇸
Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States
Treatment of Insomnia in Migraineurs
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- MedVadis Research Corporation
- Target Recruit Count
- 113
- Registration Number
- NCT00812214
Treatment of Insomnia and Glucose Metabolism
- Conditions
- Interventions
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2015-10-16
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 20
- Registration Number
- NCT00724282
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Safety and Efficacy of Eszopiclone With Mild to Moderate Obstructive Sleep Apnea Syndrome (OSAS)
- Conditions
- Interventions
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00685269
Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- Yale University
- Target Recruit Count
- 39
- Registration Number
- NCT00645944
- Locations
- 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States
Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 456
- Registration Number
- NCT00616655
- Locations
- 🇺🇸
Southwestern Research, Inc., Pasadena, California, United States
🇺🇸Excell Research, Oceanside, California, United States
🇺🇸California Clinical Trials Medical Group, Paramount, California, United States
Continuous Positive Airway Pressure (CPAP) Promotion And Prognosis - the Army Sleep Apnea Program (ASAP)
- Conditions
- Interventions
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2009-02-26
- Lead Sponsor
- Walter Reed Army Medical Center
- Target Recruit Count
- 154
- Registration Number
- NCT00612157
- Locations
- 🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States
Eszopiclone for Improving Sleep in Multiple Sclerosis (MS)
- Conditions
- Interventions
- First Posted Date
- 2008-01-15
- Last Posted Date
- 2009-01-05
- Lead Sponsor
- University of Vermont
- Target Recruit Count
- 30
- Registration Number
- NCT00594087
- Locations
- 🇺🇸
University of Vermont, Burlington, Vermont, United States
Sleep Loss and Mechanisms of Impaired Glucose Metabolism
- First Posted Date
- 2007-11-09
- Last Posted Date
- 2013-12-10
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT00555750
- Locations
- 🇺🇸
Brigham and Women's Hospital, Division of Sleep Medicine, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.